Longevity gene therapy and AI – What is on the horizon?

Longevity Gene Therapy

Longevity gene therapy and AI – What is on the horizon?

Gene therapy holds promise for extending human lifespan and enhancing healthspan by targeting genes associated with aging processes. Longevity gene therapy, particularly interventions focusing on genes like TERT (telomerase reverse transcriptase), Klotho, and Myostatin, is at the forefront of experimental research. Companies such as Bioviva, Libella, and Minicircle are pioneering these interventions, albeit with varying degrees of transparency and scientific rigor.

TERT, Klotho, and Myostatin in Longevity

  • TERT: The TERT gene encodes for an enzyme essential in telomere maintenance, which is linked to cellular aging. Overexpression of TERT in model organisms has shown potential in lengthening telomeres, potentially delaying aging.
  • Klotho: This gene plays a crucial role in regulating aging and lifespan. Klotho protein has been associated with multiple protective effects against age-related diseases.
  • Myostatin: Known for its role in regulating muscle growth, inhibiting Myostatin can result in increased muscle mass and strength, which could counteract some age-related physical decline.

The Experimental Nature of Longevity Gene Therapy

The application of gene therapy for longevity remains largely experimental. Most available data come from preclinical studies, primarily in animal models. Human data are scarce, raising questions about efficacy, safety, and potential long-term effects. The ethical implications of these experimental treatments, especially in the absence of robust data, are significant, touching on issues of access, consent, and potential unforeseen consequences.

Companies Offering Longevity Gene Therapy

  • Bioviva: Notably involved in this field, Bioviva has been vocal about its endeavors in gene therapy for aging. While they have published some data from mouse studies, human data remain limited.
  • Libella and Minicircle: These companies also offer longevity gene therapies but face similar challenges in providing comprehensive human data to back their claims.

Industry Perspective vs. Public Discourse

The discourse around longevity gene therapy is predominantly shaped by those within the industry, such as Liz Parrish of Bioviva and Bryan Johnson. While their insights are valuable, they may also be biased towards promoting their interventions. The lack of widespread discussion on platforms like Reddit and Twitter, especially from independent sources or those outside the industry, points to a need for greater transparency and peer-reviewed research.

Longevity Gene Therapy
Longevity Gene Therapy

Ethical and Regulatory Considerations

The ethical and regulatory landscape for gene therapy is complex, particularly for treatments aimed at non-disease conditions like aging. The experimental status of longevity gene therapies raises significant ethical questions, particularly around informed consent and the potential long-term impacts. Regulatory bodies are tasked with balancing the potential benefits of such innovative treatments against the risks and ethical concerns, requiring a robust framework for clinical trials and approval processes.

Longevity Gene Therapy and AI

Integrating Artificial Intelligence (AI) into longevity gene therapy represents a groundbreaking intersection of biotechnology and computational sciences. AI and machine learning algorithms are increasingly employed to decipher complex biological data, predict the impacts of genetic modifications, and optimize therapy designs. In the context of longevity gene therapy, AI can analyze vast datasets from genomics, proteomics, and metabolomics to identify new therapeutic targets, understand the intricate mechanisms of aging, and predict individual responses to gene therapies. This computational power enables researchers to simulate the effects of gene editing or modulation before actual clinical application, enhancing the precision and safety of therapies. Furthermore, AI-driven platforms facilitate the personalized tailoring of gene therapy interventions, taking into account the unique genetic makeup of each individual, which is crucial for effective and minimally invasive treatment strategies. The synergy between AI and longevity gene therapy accelerates the pace of discovery and development in this field, promising more rapid translation of research findings into clinical applications that could extend human healthspan and lifespan.

Moving Forward

For longevity gene therapy to advance from experimental to accepted medical practice, several key developments are needed:

AI Unraveled: Demystifying Frequently Asked Questions on Artificial Intelligence (OpenAI, ChatGPT, Google Bard, Generative AI, Discriminative AI, xAI, LLMs, GPUs, Machine Learning, NLP, Promp Engineering)
  • Robust Human Clinical Trials: Rigorous, peer-reviewed clinical trials involving human participants are essential to establish the safety and efficacy of gene therapies for longevity.
  • Transparency and Peer Review: Open sharing of data and peer-reviewed publication of results can help build credibility and foster a more informed public discourse.
  • Ethical and Regulatory Frameworks: Developing clear ethical guidelines and regulatory pathways for these therapies will be crucial in ensuring they are deployed responsibly.

The future of longevity gene therapy is fraught with challenges but also holds immense promise. As the field evolves, a multidisciplinary approach involving scientists, ethicists, regulators, and the public will be crucial in realizing its potential in a responsible and beneficial manner.

Longevity gene therapy and AI: Annex

What are the top 10 most promising potential longevity therapies being researched?

I think the idea of treating aging as a disease that’s treatable and preventable in some ways is a really necessary focus. The OP works with some of the world’s top researchers using HBOT as part of that process to increase oxygen in the blood and open new pathways in the brain to address cognitive decline and increase HealthSpan (vs. just lifespan). Pretty cool stuff!

HBOT in longevity research stands for “hyperbaric oxygen therapy.” It has been the subject of research for its potential effects on healthy aging. Several studies have shown that HBOT can target aging hallmarks, including telomere shortening and senescent cell accumulation, at the cellular level. For example, a prospective trial found that HBOT can significantly modulate the pathophysiology of skin aging in a healthy aging population, indicating effects such as angiogenesis and senescent cell clearance. Additionally, research has demonstrated that HBOT may induce significant senolytic effects, including increasing telomere length and decreasing senescent cell accumulation in aging adults. The potential of HBOT in healthy aging and its implications for longevity are still being explored, and further research is needed to fully understand its effects and potential applications.

If you are looking for an all-in-one solution to help you prepare for the AWS Cloud Practitioner Certification Exam, look no further than this AWS Cloud Practitioner CCP CLF-C02 book

2- Are they also looking into HBOT as a treatment for erectile dysfunction?

Definitely! Dr. Shai Efrati has been doing research around that and had a study published in the Journal of Sexual Medicine. Dr. Efrati and his team found that 80% of men “reported improved erections” after HBOT therapy: https://www.nature.com/articles/s41443-018-0023-9

3- I think cellular reprogramming seems to be one of the most promising approaches https://www.lifespan.io/topic/yamanaka-factors/

4-Next-gen senolytics (eg, Rubedo, Oisin, Deciduous).

Cellular rejuvenation aka partial reprogramming (as someone else already said) but not just by Yamanaka (OSKM) factors or cocktail variants but also by other novel Yamanaka-factor alternatives.

Stem cell secretions.

Treatments for aging extra-cellular matrix (ECM).

5- Rapamycin is the most promising short term.

I see a lot of people saying reprogramming, and I think the idea is promising but as someone who worked on reprogramming cells in vitro I can tell you that any proof of concepts in vivo large animal models is far aways.

6- Blood focused therapies ( dilution, plasma refactoring, e5, exosomes) perhaps look at yuvan research.

7- I think plasmapheresis is a technology most likely to be proven beneficial in the near term and also a technology that can be scaled and offered for reasonable prices.

8- Bioelectricity, if we succeed in interpreting the code of electrical signals By which cells communicate , we can control any tissue growth and development including organs regeneration

Djamgatech: Build the skills that’ll drive your career into six figures: Get Djamgatech.

9- Gene therapy and reprogramming will blow the lid off the maximum lifespan. Turning longevity genes on/expressing proteins that repair cellular damage and reversing epigenetic changes that occur with aging.

10- I don’t think anything currently being researched (that we know of) has the potential to take us to immortality. That’ll likely end up requiring some pretty sophisticated nanotechnology. However, the important part isn’t getting to immortality, but getting to LEV. In that respect, I’d say senolytics and stem cell treatments are both looking pretty promising. (And can likely achieve more in combination than on their own.)

11- Spiroligomers to remove glucosepane from the ECM.

12- Yuvan Research. Look up the recent paper they have with Steve Horvath on porcine plasma fractions.

13- This OP thinks most of the therapies being researched will end up having insignificant effects. The only thing that looks promising to me is new tissue grown from injected stem cells or outright organ replacement. Nothing else will address DNA damage, which results in gene loss, disregulation of gene expression, and loss of suppression of transposable elements.

14- A couple that haven’t been mentioned:


  • The killer T-cells that target MR-1 and seem to be able to find and kill all common cancer types.

  • Also Maia Biotech’s THIO (“WILT 2.0”)

Mitochondria: Mitochondrial infusion that lasts or the allotopic expression of the remaining proteins SENS is working on.

15- Look for first updates coming from altos labs.

Altos Labs is a biotechnology research company focused on unraveling the deep biology of cell rejuvenation to reverse disease and develop life extension therapies that can halt or reverse the human aging process. The company’s goal is to increase the “healthspan” of humans, with longevity extension being an “accidental consequence” of their work. Altos Labs is dedicated to restoring cell health and resilience through cell rejuvenation to reverse disease, injury, and disabilities that can occur throughout life. The company is working on specialized cell therapies based on induced pluripotent stem cells to achieve these objectives. Altos Labs is known for its atypical focus on basic research without immediate prospects of a commercially viable product, and it has attracted significant investment, including a $3 billion funding round in January 2022. The company’s research is based on the fundamental biology of cell rejuvenation, aiming to understand and harness the ability of cells to resist stressors that give rise to disease, particularly in the context of aging.

Ace the Microsoft Azure Fundamentals AZ-900 Certification Exam: Pass the Azure Fundamentals Exam with Ease

16not so much a “therapy” but I think research into growing human organs may be very promising long term. Being able to get organ transplants made from your own cells means zero rejection issues and no limitations of supply for transplants. Near term drugs like rampamycin show good potential for slowing the aging process and are in human trials.

What is biological reprogramming technology?

Biological reprogramming technology involves the process of converting specialized cells into a pluripotent state, which can then be directed to become a different cell type. This technology has significant implications for regenerative medicine, disease modeling, and drug discovery. It is based on the concept that a cell’s identity is defined by the gene regulatory networks that are active in the cell, and these networks can be controlled by transcription factors. Reprogramming can be achieved through various methods, including the introduction of exogenous factors such as transcription factors. The process of reprogramming involves the erasure and remodeling of epigenetic marks, such as DNA methylation, to reset the cell’s epigenetic memory, allowing it to be directed to different cell fates. This technology has the potential to create new cells for regenerative medicine and to provide insights into the fundamental basis of cell identity and disease.

See also

Links to external Longevity-related sites



Longevity Wiki

Outline of Life Extension on Wikipedia

Index of life extension related Wikipedia articles

Accelerate cure for Alzheimers
Aging in Motion
Aging Matters
Aging Portfolio
Alliance for Aging Research
Alliance for Regenerative Medicine
American Academy of Anti-Aging Medicine
American Aging Association
American Federation for Aging Research
American Society on Aging
Blue Zones – /r/BlueZones
Brain Preservation Foundation
British Society for Research on Aging
Calico Labs
Caloric Restriction Society
Church of Perpetual Life
Coalition for Radical Life Extension
Dog Aging Project
ELPI Foundation for Indefinite Lifespan
Fight Aging! Blog
Found My Fitness
Friends of NIA
Gerontology Wiki
Global Healthspan Policy Institute
Health Extension
Healthspan Campaign
Humanity+ magazine
Humanity+ wiki
International Cell Senescence Association
International Longevity Alliance
International Longevity Centre Global Alliance
International Society on Aging and Disease
Juvena Therapeutics
Leucadia Therapeutics
Life Extension Advocacy Foundation
Life Extension Foundation
Lifeboat Foundation
Longevity History
Longevity Vision Fund
Loyal for Dogs Lysoclear
MDI Biological Laboratory
Methuselah Foundation
New Organ Alliance
Oisin Biotechnologies
Organ Preservation Alliance
Palo Alto Longevity Prize
Rejuvenaction Blog
Rubedo Life Sciences
Stealth BioTherapeutics
The War On Aging
Unity Biotechnologies
Water Bear Lair

Good Informational Sites:

Programmed Aging Info
Senescence Info
Experimental Gerontology Journal
Mechanisms of Ageing and Development Journal

Schools and Academic Institutions:

Where to do a PhD on aging – a list of labs

Alabama Research Institute on Aging
UT Barshop Institute
Biogerontology Research Foundation
Buck Institute
Columbia Aging Center
Gerontology Research Group
Huffington Center on Aging
Institute for Aging Research – Harvard
Iowa State University Gerontology
Josh Mitteldorf
Longevity Consortium
Max Planck Institute for Biology of Aging – Germany
MIT Agelab
National Institute on Aging
Paul F. Glenn Center for Aging Research – University of Michigan
PennState Center for Healthy Aging
Princeton Longevity Center
Regenerative Sciences Institute
Kogod Center on Aging – Mayo clinic
Salk Institute
Stanford Center on Longevity
Stanford Brunet Lab
Supercenterian Research Foundation
Texas A&M Center for translational research on aging
Gerontological Society of America
Tufts Human Nutrition and Aging Research
UAMS Donald Reynolds Center on Aging
UCLA Longevity Center
UCSF Memory and Aging Center
UIC Center for research on health and aging
University of Iowa Center on Aging
University of Maryland Center for research on aging
University of Washington Biology of Aging
USC School of Gerontology
Wake Forest Institute of Regenerative Medicine
Yale Center for Research on Aging

A Daily Chronicle of AI Innovations in February 2024

  • AI and online communities
    by /u/mcksis (Artificial Intelligence Gateway) on February 26, 2024 at 9:16 pm

    Interesting article on effects of AI on online communities. Check out the paragraph and subsequent graph of the paragraph titled “ChatGPT Still Does Not Substitute for Human Social Connections”. Go Reddit!! https://m-cacm.acm.org/magazines/2024/3/280089-generative-ai-degrades-online-communities/fulltext submitted by /u/mcksis [link] [comments]

  • Looking for an AI that would provide translation
    by /u/utkubaba9581 (Artificial Intelligence Gateway) on February 26, 2024 at 8:56 pm

    I have an online business that is relatively scaled, and I have multiple documents that I need to translate into multiple languages. Since the amount that needs to be translated is quite high, I cannot easily hire a freelance translator or a service without going out of budget. Are there AI services that are advanced enough to mass translate documents from English to an X language, in a fluent, formal tone? Free or paid. Thanks a ton in advance. submitted by /u/utkubaba9581 [link] [comments]

  • Am I using ChatGPT wrong, or is ChatGPT the wrong tool for me?
    by /u/Totally_Not_Evil (Artificial Intelligence Gateway) on February 26, 2024 at 8:04 pm

    Hey all, I've been dabbling in writing and im a total noob so I'm trying to use ChatGPT to help me aggregate different ideas so I can pick what I like. I've been trying to tell it to create general outlines, and it just sucks at following the parameters I give it. I'll say: "The setting is X The characters are Y The general story beats are Z Generate a 3 sentence chapter outline for chapters A, B, and C." And it'll be like "cool here's 4 sentences on the whole story." What am I doing wrong, and are there any better tools for what I'm looking for? submitted by /u/Totally_Not_Evil [link] [comments]

  • I am working on a project that uses AI for Personal Growth. By discovering how AI can be used to for personal growth and helping people achieve win-win goals, we can build AI Systems that has humanities best interest at heart.
    by /u/TrendingTechGuy (Artificial Intelligence Gateway) on February 26, 2024 at 7:30 pm

    Imagine that the AI would work well in a goal directed path. The overall path is personalized to the user's Mission in life. Then to achieve the mission, goals are broken down into steps. Each step has its own set of sub-goals. When each goal is complete, then we move to the next step and so on. The overall path is personalized but follows well known and researched steps. What are your thoughts about the project? submitted by /u/TrendingTechGuy [link] [comments]

  • You can now make any image into interactive, playable enviornments using Google's Genie
    by /u/holy_moley_ravioli_ (Artificial Intelligence) on February 26, 2024 at 6:31 pm

    submitted by /u/holy_moley_ravioli_ [link] [comments]

  • AGBA
    by /u/NASDQplayer97 (Artificial Intelligence Gateway) on February 26, 2024 at 6:22 pm

    submitted by /u/NASDQplayer97 [link] [comments]

  • [D] Question on generating embeddings with Transformer Encoder-Decoder
    by /u/Primary-Wasabi292 (Artificial Intelligence Gateway) on February 26, 2024 at 5:47 pm

    submitted by /u/Primary-Wasabi292 [link] [comments]

  • Local model for video enhancement
    by /u/KahlessAndMolor (Artificial Intelligence Gateway) on February 26, 2024 at 5:36 pm

    Hello folks, ​ I have some old Super 8 film that was taken back in the 60s. It is blurry and too light. I'm hoping I can enhance it, remove all the static, upscale, and bring up the colors some. ​ I found one paid service (cutout pro) but it is like $140. ​ I have 64GB of RAM and 16GB of VRAM, and I can leave my machine running for hours and hours. ​ Is there a product/model that will let me do this task on my local machine? ​ Thank you! ​ ​ submitted by /u/KahlessAndMolor [link] [comments]

  • AI and the LLM inflection point
    by /u/daimon_tok (Artificial Intelligence Gateway) on February 26, 2024 at 5:26 pm

    I'm really struggling to understand something. I've worked fairly deep in the world of AI for quite some time, at least 10 years. Over those 10 years I've worked with a wide variety of machine learning models, massive data sets, Hadoop clusters, learned many MLOps lessons, put a variety of models into production at volume, etc. I could go on, but my main point is that I've always felt like I understand the applications of AI very well, even if the understanding of the technology is never ending. I also feel like I have a pretty intimate understanding of the limitations based on data that a lot of AI faces. Enter the LLM hockey stick. I was initially excited because I had a lot of interest in BERT and the general category of conversational chatbots. I jumped at GPT-*, Midjourney, dall e, etc. I tried to drive as much value as I could from each. I've asked countless folks who are very excited about the value they derive from the post hockey stick AI. What I found is what feels like a level of cognitive dissonance. There's no question that AI, specifically diverse forms of AI that already had momentum prior to the LLM hockey stick, are driving value. But what I did not find is much substantive value from the AI that quickly became household names, which are primarily LLM based. In addition, I personally struggled to derive much value from nearly anything I tried, I found a ton of novelty and some definite utility but very little beyond that. At this point I just think I'm missing something. I would love to hear from everyone else how the post hockey stick batch of AI technologies is being used in any tangible and practical sense. I basically just want to build a list of the new applications that I feel like I'm not aware of so if I can learn them. submitted by /u/daimon_tok [link] [comments]

  • NASDAQ: $AGBA AGBA Group Appoints Bob Diamond as Chairman and Announces Atlas Merchant Capital as Strategic Advisor
    by /u/NASDQplayer97 (Artificial Intelligence Gateway) on February 26, 2024 at 5:12 pm

    Mr. Bob Diamond, Founding Partner and Chief Executive Officer of Atlas Merchant Capital and Chairman of AGBA Group said: “I am thrilled to be working with Wing-Fai and AGBA and for Atlas Merchant Capital to be a strategic advisor. I look forward to our companies growing, working and investing together.” HONG KONG, Sept. 19, 2023 (GLOBE NEWSWIRE) -- NASDAQ-listed, AGBA Group Holding Limited (“AGBA”, “The Group”), the leading one-stop financial supermarket in Hong Kong, announced the appointment of Mr. Bob Diamond as the Chairman of the AGBA Board, effective immediately. AGBA has also engaged Atlas Merchant Capital (“Atlas”) as its strategic advisor for its forthcoming phase of expansion. Mr. Diamond brings decades of financial services experience, an established leadership track record, as well as deep credibility in global finance to the Board. Mr. Diamond is the CEO of Atlas and formerly served as CEO of Barclays Bank PLC. Atlas is a global investment firm founded by Mr. Diamond and Mr. David Schamis, offering debt and equity investment strategies to invest in public and private markets through its differentiated expertise in financial services and credit markets. AGBA has previously stated that a primary reason for its listing on NASDAQ is to expand its product-base and establish a global presence. With the addition of Mr. Diamond, the Group firmly believes that AGBA will be able to accelerate the implementation of its strategic vision, setting the stage for long-term success. AGBA is Asia’s leading investment advisor (equivalent to a Registered Investment Advisor “RIA” in the U.S.), providing financial advice and distributing life insurance and asset management products to individuals. The Group has long identified significant demand for unique investment assets in the United States from clients across Asia, especially in the Greater Bay Area of China. The strategic advisory relationship with Atlas represents a significant milestone for AGBA. AGBA believes in the capabilities and strengths of OnePlatform, its integrated digital platform for financial intermediaries. The technology and infrastructure of OnePlatform are designed and built to be portable to key markets in the U.S., Canada and the United Kingdom. Working in collaboration with Atlas as a strategic advisor, the Group seeks to drive the global expansion of OnePlatform through organic growth, strategic partnerships, and acquisitions. Mr. Bob Diamond, Founding Partner and Chief Executive Officer of Atlas Merchant Capital and Chairman of AGBA Group said: “I am thrilled to be working with Wing-Fai and AGBA and for Atlas Merchant Capital to be a strategic advisor. I look forward to our companies growing, working and investing together.” Mr. Wing-Fai Ng, Group President, AGBA Group Holding Limited said: “Bob, David, Jeroen Nieuwkoop (our Chief Strategy Officer) and I have known and worked with each other for decades. All of us at AGBA are elated to be working with Bob, David and the Atlas team in capturing growth and leading transformation in our financial industries. It is a privilege to be working with them again. Personally, there is nothing in business better than working together with consummate professionals you know and trust.” ​ ​ submitted by /u/NASDQplayer97 [link] [comments]

error: Content is protected !!